Motley Fool Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $335K | Buy |
2,667
+209
| +9% | +$26.3K | 0.02% | 193 |
|
|
2025
Q1 | $272K | Buy |
2,458
+209
| +9% | +$23.1K | 0.02% | 203 |
|
|
2024
Q4 | $307K | Buy |
2,249
+220
| +11% | +$30K | 0.02% | 194 |
|
|
2024
Q3 | $232K | Sell |
2,029
-24
| -1% | -$2.74K | 0.01% | 199 |
|
|
2024
Q2 | $288K | Sell |
2,053
-14
| -0.7% | -$1.96K | 0.02% | 185 |
|
|
2024
Q1 | $285K | Buy |
2,067
+197
| +11% | +$27.2K | 0.02% | 201 |
|
|
2023
Q4 | $246K | Sell |
1,870
-168
| -8% | -$22.1K | 0.02% | 201 |
|
|
2023
Q3 | $229K | Buy |
+2,038
| New | +$229K | 0.02% | 204 |
|
|
2023
Q1 | – | Sell |
-1,721
| Closed | -$206K | – | 172 |
|
|
2022
Q4 | $206K | Buy |
+1,721
| New | +$206K | 0.02% | 207 |
|
|
2022
Q1 | – | Sell |
-44
| Closed | -$4K | – | 284 |
|
|
2021
Q4 | $4K | Buy |
+44
| New | +$4K | ﹤0.01% | 244 |
|